Chronic Pain Treatment Market

Currently, there too many deaths and side-effects reported due to over use of opioids. The shift from opioid to non-opioid is already happening. It is fair to state that a majority of the patients will use non-opioids rather than opioids in the next ten years

-Director, US based device manufacturer

Chronic Pain Treatment Market Overview

The global chronic pain treatment market, valued at USD 78.0 billion in 2024, is projected to reach USD 83.4 billion in 2025 and USD 155.2 billion by 2035, representing a CAGR of 6.4% during the forecast period.

To learn more about this report, request a free sample copy

Chronic pain refers to the psychophysiological response to an underlying clinical condition, which is observed to persist for a duration greater than six months and is generally unresponsive to multiple treatment regimens. It is estimated that more than 1.5 billion individuals across the world suffer from this type of pain.

Some of the most common physiological conditions that are characterized by a chronic sensation of pain include migraine, lower back pain, pain associated with cancer, arthritis-related pain and neurogenic pain. Owing to the rapid onset of their medicinal effect, which offers immediate relief with high efficacy, opioids are still considered to be one of the most widely used pharmacological interventions for the management of moderate to severe forms of pain. However, these drugs are known to induce a euphoric state upon intake, often causing patients to abuse them; increased recreational use of opioids has also been shown to lead to drug addiction. The over-prescription of such medicinal products, which promotes their misuse, is considered as one of the root causes of the opioid crisis. In a recent article, 11.5 million individuals were reported to have been caught misusing prescription opioids, while over 42,000 died from opioid overdose, in the US alone. Moreover, opioid abuse was estimated to have been responsible for over USD 500 billion worth of economic deficit (in the US) due to loss of productivity and healthcare costs.

The opioid crisis has prompted drug manufacturers to develop non-addictive, non-narcotic-based therapeutics / analgesics for the management of pain. Unlike opioids, non-opioid drugs do not affect receptors present in the brain and, thus, are not addictive. These drugs work directly on injured / diseased body tissues and generally block the production of prostaglandins by inhibiting the cyclooxygenase (COX) enzyme at the site of injury / infection, thereby, decreasing the generation of pain mediators within the peripheral nervous system. Additionally, there are various pain management devices that have been reported to significantly reduce or eliminate the need for pharmacological interventions. Such devices are increasingly being used to treat a variety of clinical conditions that are characterized by chronic pain and offer the convenience of being used in the homecare setting as well. However, it is imperative for patients to consult qualified healthcare professionals, who have the required understanding of such therapeutic options, prior to using such devices.

Key Companies in Chronic Pain Treatment Market

Examples of key companies engaged in developing non-opioid drugs and pain management devices for chronic pain (which have also been profiled in this market report; the complete list of companies is available in the full report) include Stimwave, BlueWind Medical, Omron Healthcare, Cefaly Technologies, Prizm Medical, PainPod, Neurometrix, Chattem, Silk’n Therapy and ElectroMedical Technologies. This chronic pain treatment market report includes an easily searchable excel database of all the companies developing chronic pain management devices and non-opioid drugs, worldwide.

Recent Developments in Chronic Pain Treatment Market

• In June 2026, the USFDA granted Breakthrough Therapy Designation to VER-01, a cannabis-derived oral therapy for chronic low back pain.
• In April 2026, Contineum Therapeutics reported positive topline data from its Phase 1b trial of PIPE-791 for chronic osteoarthritis and low back pain.
• In April 2026, Dogwood Therapeutics announced FDA acceptance of its Investigational New Drug application for SP16, targeting chemotherapy-induced pain and neuropathy.
• In January 2026, Levicept announced FDA acceptance of its IND application for LEVI-04, a potential disease-modifying osteoarthritis treatment addressing chronic pain.

Scope of the Chronic Pain Treatment Market Report

The Chronic Pain Treatment Market report provides an extensive study on the current market landscape, pain management market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the chronic pain treatment market. The market research report also features a detailed overview of the devices that are used for the treatment / management of pain associated with chronic clinical conditions.

Amongst other elements, the market research report includes:

• A detailed assessment of the current market landscape of drugs being developed for the treatment of chronic pain, providing information on their respective developer(s), phase of development (clinical, and preclinical / discovery), type of molecule (small molecule and biologic), indication (nociceptive and neuropathic), mechanism of action (channel blockers, receptor antagonists, protein pathway modulators and others) and route of administration (intra-articular, intravenous, intranasal,  intranasal, intrathecal, oral, subcutaneous, topical and transdermal).
• An in-depth analysis of the product pipeline and developer companies, featuring [A] a mirror analysis highlighting the relative popularity of different disease indications based on the number of molecules available / under development for each indication and the number of companies involved, [B] a logo landscape of the various industry players involved in chronic pain treatment market, distributed on the basis of location of headquarters and company size (small-sized, mid-sized and large), [C] a heptagon representation highlighting the distribution of marketed and pipeline molecules based on their respective mechanisms of action, and [D] a funnel analysis highlighting the distribution of molecules on the basis of stage of development, route of administration and treatment type.
• An analysis highlighting the key unmet needs across chronic pain, featuring insights generated from data sourced from patient blogs, recent scientific publications, social media posts and the views of key opinion leaders expressed on various online platforms.
• An elaborate discussion on lifecycle management strategies, describing how different companies are using various methods to prolong patent age and, thereby, expand marketing exclusivity in order to exploit the revenue generation potential of their proprietary products. The section also includes detailed case studies elaborating on diverse lifecycle management strategies of marketed drugs that are nearing patent expiry.
• Comprehensive profiles of drugs that are in phase III of clinical development, with information on developer companies (including location of headquarters and year of establishment), type of molecule, mechanism of action, current status of development, route of administration, information on clinical trials and key developments (if available).
• A detailed assessment of the current market landscape of various devices that are being developed for chronic pain management, highlighting information on developer (size of company and location of headquarters), mechanism of action (electrical stimulation, electromagnetic pulse, heat therapy, light therapy, radiofrequency stimulation and others), site of application on the body (head, arm, knees and other areas), modality of the device (invasive and non-invasive), and treatment requirements (at home and at hospitals / outpatient clinics), and type of device (wearable, hand-held and implants).
• An insightful 2X2 competitive analysis for the various devices, highlighting the most important products based on the modality of device, treatment requirement, type of device, and supplier power (based on size of employee base of the company). The chapter also includes profiles of devices that emerged as relatively superior (based on the analysis); each profile features details on the developer (location of headquarters and year of establishment), approval year, mechanism of action, key features and key developments.
• An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (related to both technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements and others
• An analysis of investments made at various stages of product development; these include seed financing, venture capital financing, debt financing and grants / awards, received by companies that are operating in chronic pain treatment market.

The key objective of chronic pain treatment market report is to provide a detailed market analysis in order to estimate the existing pain management market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for chronic pain treatment market during the forecast period. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term, for the forecast period, till 2035. The market report includes a detailed market segmentation on the basisof indication (chronic back pain, lumbar radiculopathy, migraine, osteoarthritis and neuropathic pain), type of molecule (small  molecule and biologic), mechanism of action (CGRP inhibitors, COX/ NGF inhibitors, TRPV1 receptor antagonists, channel blockers and others) and geography (North America, Europe, Asia Pacific and rest of the World). In addition, the market report features an opportunity analysis for the chronic pain management devices market. The opinions and insights presented in this market report were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in chronic pain treatment market. The market research report features detailed transcripts of interviews held with Director of Clinical Affairs & New Markets, Small Company, US, Chief Advocacy Officer, Mid-sized Company, US, Chief Executive Officer, Small Company, US and Chief Executive Officer, Small Company, US. All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is chronic pain?

Answer: Chronic pain refers to the psychophysiological response to an underlying clinical condition, which is observed to persist for a duration greater than six months and is generally unresponsive to multiple treatment regimens.

Question 2: How big is the chronic pain treatment market?

Answer: The chronic pain treatment market size is estimated to be worth USD 83.4 billion in 2025.

Question 3: What is the projected market growth of the chronic pain treatment market?

Answer: The chronic pain treatment market is expected to grow at compounded annual growth rate (CAGR) of 6.4% till 2035.

Question 4: Who are the leading companies in the chronic pain treatment industry?

Answer: Examples of key companies engaged in chronic pain treatment market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Stimwave, BlueWind Medical, Omron Healthcare, Cefaly Technologies, Prizm Medical, PainPod, Neurometrix, Chattem, Silk’n Therapy and ElectroMedical Technologies.

Question 5: How many chronic pain management devices are currently available?

Answer: Over 120 chronic pain treatment devices are currently available in the market.

Question 6: How many companies are currently engaged in the chronic pain treatment industry?

Answer: Presently, over 100 companies are engaged in the chronic pain treatment market.